<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37937429</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2310-6972</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Biomeditsinskaia khimiia</Title><ISOAbbreviation>Biomed Khim</ISOAbbreviation></Journal><ArticleTitle>Perspectives for the creation of a new type of vaccine preparations based on pseudovirus particles using polio vaccine as an example.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>280</EndPage><MedlinePgn>253-280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18097/PBMC20236905253</ELocationID><Abstract><AbstractText>Traditional antiviral vaccines are currently created by inactivating the virus chemically, most often using formaldehyde or Î²-propiolactone. These approaches are not optimal since they negatively affect the safety of the antigenic determinants of the inactivated particles and require additional purification stages. The most promising platforms for creating vaccines are based on pseudoviruses, i.e., viruses that have completely preserved the outer shell (capsid), while losing the ability to reproduce owing to the destruction of the genome. The irradiation of viruses with electron beam is the optimal way to create pseudoviral particles. In this review, with the example of the poliovirus, the main algorithms that can be applied to characterize pseudoviral particles functionally and structurally in the process of creating a vaccine preparation are presented. These algorithms are, namely, the analysis of the degree of genome destruction and coimmunogenicity. The structure of the poliovirus and methods of its inactivation are considered. Methods for assessing residual infectivity and immunogenicity are proposed for the functional characterization of pseudoviruses. Genome integrity analysis approaches, atomic force and electron microscopy, surface plasmon resonance, and bioelectrochemical methods are crucial to structural characterization of the pseudovirus particles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhdanov</LastName><ForeName>D D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivin</LastName><ForeName>Yu Yu</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shishparenok</LastName><ForeName>A N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraevskiy</LastName><ForeName>S V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanashenko</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agafonova</LastName><ForeName>L E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumyantseva</LastName><ForeName>V V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gnedenko</LastName><ForeName>O V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinyaeva</LastName><ForeName>A N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovpak</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishmukhametov</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archakov</LastName><ForeName>A I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Biomed Khim</MedlineTA><NlmUniqueID>101196966</NlmUniqueID><ISSNLinking>2310-6905</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical><Chemical><RegistryNumber>6RC3ZT4HB0</RegistryNumber><NameOfSubstance UI="D011420">Propiolactone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011420" MajorTopicYN="N">Propiolactone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">functional characterization</Keyword><Keyword MajorTopicYN="N">inactivation</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">pseudovirus</Keyword><Keyword MajorTopicYN="N">structural characterization</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37937429</ArticleId><ArticleId IdType="doi">10.18097/PBMC20236905253</ArticleId></ArticleIdList></PubmedData></PubmedArticle>